Recently Appointed Cooper Companies Director Paul Keel Buys $250,000 Stock. Does This Signal Shares are a Buy?
Keel purchased 4,701 shares at $53.18 each following a 21% year-long decline, signaling confidence in the medical device company's valuation.
Recently appointed Director Paul Keel of Cooper Companies, Inc. (COO) acquired 4,701 shares of the company's stock on September 11, 2026, as reported by a SEC Form 4 filing. The transaction, valued at $250,000 based on the weighted average purchase price of $53.18 per share, occurred at a time when the stock was trading at $53.91 per share, according to the market close on the same day.
Cooper Companies, a global leader in medical devices with approximately 15,000 employees and a market capitalization of $10.4 billion, operates in the ophthalmic and vision care sectors through its dual-segment strategy. This strategy combines the innovation in contact lenses by CooperVision with the surgical devices by CooperSurgical, creating a diversified revenue stream and cross-selling opportunities within the eye care continuum.
The company's revenue for the trailing twelve months (TTM) was reported at $4.2 billion, and net income stood at $570.3 million. This acquisition by Director Keel, given Cooper Companies' strong position in the eye care industry and its robust financials, could indicate a favorable outlook for the company's shares.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
